Enhertu (Trastuzumab Deruxtecan) Gains FDA Supplemental Efficacy Approval

On 2022-05-04, the U.S. Food and Drug Administration (FDA) approved a supplemental application for Enhertu (fam-trastuzumab deruxtecan-nxki). This approval specifically relates to the drug's efficacy, as indicated by the submission BLA 761139 S-20.

Background

Trastuzumab Deruxtecan, marketed as Enhertu, is a known therapeutic agent. Supplemental applications are submitted to the FDA when a manufacturer seeks to update or expand an existing approval. In the context of efficacy, this typically means the submission of new clinical data demonstrating the drug's effectiveness for a new indication, a different patient population, or an improved dosing regimen compared to its initial approval. These applications are critical for ensuring that drug labels reflect the most current scientific understanding and clinical utility of a medication. The sponsor for this application was DAIICHI SANKYO.

What this means

The FDA's decision to approve this supplemental application for Enhertu's efficacy signifies that new clinical evidence has been thoroughly reviewed and deemed sufficient to support an expansion or modification of its approved uses. While the specific details of the new indication or patient population are not provided in the available source data, such an approval typically broadens the therapeutic scope of the drug. For clinicians, this means that Enhertu is now approved for an additional use, which could impact treatment guidelines and patient care decisions. For patients, it may offer a new treatment option for a condition where Enhertu was not previously indicated. This process underscores the FDA's ongoing role in evaluating new data to ensure drugs remain safe and effective for their intended purposes.

Source

The information regarding this supplemental approval was obtained from the U.S. Food and Drug Administration (FDA) website. The approval for supplemental application BLA 761139 S-20 for Enhertu (fam-trastuzumab deruxtecan-nxki) was granted on 2022-05-04 and is publicly accessible on accessdata.fda.gov, under the application number BLA761139.